Autofluorescence imaging resolves early cancer treatment response in vivo

Alex Walsh, Rebecca S. Cook, H. Charles Manning, Donna J. Hicks, Alec Lafontant, Carlos L. Arteaga, Melissa C. Skala

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

NADH and FAD auto-fluorescence intensity and lifetime imaging are used to monitor breast cancer metabolism. In vivo imaging of xenograft tumors revealed metabolic differences in responsive but not resistant tumors treated with trastuzumab at earlier time points than FDG-PET.

Original languageEnglish (US)
Title of host publicationOptical Molecular Probes, Imaging and Drug Delivery, OMP 2013
StatePublished - Nov 19 2013
EventOptical Molecular Probes, Imaging and Drug Delivery, OMP 2013 - Waikoloa Beach, HI, United States
Duration: Apr 14 2013Apr 18 2013

Other

OtherOptical Molecular Probes, Imaging and Drug Delivery, OMP 2013
CountryUnited States
CityWaikoloa Beach, HI
Period4/14/134/18/13

Fingerprint

Optical Imaging
tumors
cancer
Flavin-Adenine Dinucleotide
metabolism
Heterografts
breast
NAD
Neoplasms
Fluorescence
Breast Neoplasms
life (durability)
fluorescence
Trastuzumab

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Atomic and Molecular Physics, and Optics

Cite this

Walsh, A., Cook, R. S., Manning, H. C., Hicks, D. J., Lafontant, A., Arteaga, C. L., & Skala, M. C. (2013). Autofluorescence imaging resolves early cancer treatment response in vivo. In Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013

Autofluorescence imaging resolves early cancer treatment response in vivo. / Walsh, Alex; Cook, Rebecca S.; Manning, H. Charles; Hicks, Donna J.; Lafontant, Alec; Arteaga, Carlos L.; Skala, Melissa C.

Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013. 2013.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Walsh, A, Cook, RS, Manning, HC, Hicks, DJ, Lafontant, A, Arteaga, CL & Skala, MC 2013, Autofluorescence imaging resolves early cancer treatment response in vivo. in Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013. Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013, Waikoloa Beach, HI, United States, 4/14/13.
Walsh A, Cook RS, Manning HC, Hicks DJ, Lafontant A, Arteaga CL et al. Autofluorescence imaging resolves early cancer treatment response in vivo. In Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013. 2013
Walsh, Alex ; Cook, Rebecca S. ; Manning, H. Charles ; Hicks, Donna J. ; Lafontant, Alec ; Arteaga, Carlos L. ; Skala, Melissa C. / Autofluorescence imaging resolves early cancer treatment response in vivo. Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013. 2013.
@inproceedings{ff271500cca740958ed4c9c0acfe7205,
title = "Autofluorescence imaging resolves early cancer treatment response in vivo",
abstract = "NADH and FAD auto-fluorescence intensity and lifetime imaging are used to monitor breast cancer metabolism. In vivo imaging of xenograft tumors revealed metabolic differences in responsive but not resistant tumors treated with trastuzumab at earlier time points than FDG-PET.",
author = "Alex Walsh and Cook, {Rebecca S.} and Manning, {H. Charles} and Hicks, {Donna J.} and Alec Lafontant and Arteaga, {Carlos L.} and Skala, {Melissa C.}",
year = "2013",
month = "11",
day = "19",
language = "English (US)",
isbn = "9781557529664",
booktitle = "Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013",

}

TY - GEN

T1 - Autofluorescence imaging resolves early cancer treatment response in vivo

AU - Walsh, Alex

AU - Cook, Rebecca S.

AU - Manning, H. Charles

AU - Hicks, Donna J.

AU - Lafontant, Alec

AU - Arteaga, Carlos L.

AU - Skala, Melissa C.

PY - 2013/11/19

Y1 - 2013/11/19

N2 - NADH and FAD auto-fluorescence intensity and lifetime imaging are used to monitor breast cancer metabolism. In vivo imaging of xenograft tumors revealed metabolic differences in responsive but not resistant tumors treated with trastuzumab at earlier time points than FDG-PET.

AB - NADH and FAD auto-fluorescence intensity and lifetime imaging are used to monitor breast cancer metabolism. In vivo imaging of xenograft tumors revealed metabolic differences in responsive but not resistant tumors treated with trastuzumab at earlier time points than FDG-PET.

UR - http://www.scopus.com/inward/record.url?scp=84887538934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887538934&partnerID=8YFLogxK

M3 - Conference contribution

SN - 9781557529664

BT - Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013

ER -